



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100, Albert Road,  
South Melbourne, Victoria, 3205  
Australia

Phone: +61 3 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

### BioDiem Releases Half Year Results

**Melbourne, 1 April 2021:** Australian infectious disease therapy and vaccine development company BioDiem Ltd today announced its financial results for the half year ended 31 December 2020.

#### Highlights

- Royalties and milestone payments from the licences of BioDiem's LAIV technology of \$328,243 for the period, compared to \$122,617 in December 2019.
- Profit of \$35,887 for the period compared to a loss of \$169,284 for the corresponding previous period.
- BioDiem's licensee in China, Changchun BCHO Biotechnology Company launched their intranasal LAIV seasonal influenza vaccine in the reporting period. BioDiem earns royalties on sales of the LAIV product in China.
- BioDiem's subsidiary Opal Biosciences Ltd reviewed its strategy to include manufacturing operations and is in discussion with a high quality revenue-generating business regarding a merger.

#### Key Results Summary

		% change from previous corresponding period		A\$
Revenue from ordinary activities	Up	139%		\$405,500
Loss from ordinary activities	Down	90%		(22,148)
Net loss for the half year attributable to Non-controlling interest	Down	0.35%		(58,035)
Net loss for the half year attributable to Owners of BioDiem Limited	Down	121%		35,887

#### Other Information

No dividends have been declared or are expected to be declared in the remainder of the year.

- ENDS -

#### About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine

and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licencees:

- Changchun BCHT Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India's Nasovac-S™ is marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

### **About Opal Biosciences Ltd**

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives.

For more information, please visit [www.opalbiosciences.com](http://www.opalbiosciences.com).

### **Further information**

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences